Neena M. Patil - Feb 27, 2025 Form 4 Insider Report for Jazz Pharmaceuticals plc (JAZZ)

Signature
By: /s/Adam Guttmann, as attorney in fact For: Neena M Patil
Stock symbol
JAZZ
Transactions as of
Feb 27, 2025
Transactions value $
-$550,506
Form type
4
Date filed
3/3/2025, 07:18 PM
Previous filing
Jan 22, 2025
Next filing
Mar 7, 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction JAZZ Ordinary Shares Sale -$551K -3.8K -10.24% $144.87 33.3K Feb 27, 2025 Direct F1
transaction JAZZ Ordinary Shares Award $0 +12.5K +37.57% $0.00 45.8K Feb 27, 2025 Direct F2
transaction JAZZ Ordinary Shares Award $0 +5.78K +12.61% $0.00 51.6K Feb 27, 2025 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $144.81 to $144.88. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F2 These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2025, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years.
F3 These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units will vest in full on June 30, 2026.